Testing a new drug for advanced solid tumours
Part of Cancer clinical trials.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: non-small cell lung cancer, head and neck squamous cell cancer, triple negative breast cancer, esophageal squamous cell cancer, bladder cancer, vulvar cancer, or cervical cancer.
- Your cancer is advanced or has spread and standard treatments are no longer working or you cannot tolerate them.
- You are 18 years or older.
- You are able to take care of yourself (ECOG performance status of 0 or 1).
- You have at least one measurable tumour outside the brain that can be tracked.
- You have not had certain heart problems, recent heart attacks, strokes, or blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BI 3810944 for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and helps shrink tumors.
This study tests a new drug, BI 4060107, in people with advanced solid tumors. It is a phase 1 trial to find a safe dose and see how well people tolerate it, potentially offering a new option when standard treatments have stopped working.
This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.
This trial tests different doses of a new drug (BI 3820768) in people with advanced solid tumors, specifically germ cell tumors, endometrial cancer, or ovarian cancer. The goal is to see if the drug is safe and how well it works.
This study tests a new investigational drug called BI 3968621, given either by itself or with another drug called ezabenlimab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe and effective doses and see if the combination helps shrink tumors or slow their growth.
This trial tests an experimental drug, BA1203, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and whether it can help shrink tumors.
Hear when a new Solid Tumours trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.